Eupraxia Pharmaceuticals Inc. (EPRX) Stock Score, Valuation & Financial Research

Eupraxia Pharmaceuticals Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for EPRX

Eupraxia Pharmaceuticals Inc. does not currently have a complete Wall Street Score. The stored market price is USD 9.10. These figures are a research snapshot, not a buy or sell recommendation.

What Eupraxia Pharmaceuticals Inc. does

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of proprietary, locally delivered, extended-release drug delivery technologies, specifically its DiffuSphere platform, to address unmet medical needs.

Products and services

  • The company develops extended-release drug delivery products, primarily utilizing its proprietary DiffuSphere technology, with lead candidates including EP-104GI for eosinophilic esophagitis.

Brands and product families

  • DiffuSphere — Proprietary polymer-based micro-sphere technology platform. Source

Business strengths to evaluate

  • Proprietary DiffuSphere technology platform for targeted drug delivery Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

EPRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 9.10
Market capitalization:
304.67M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -50.22M
Free cash flow:
USD -29.63M
Cash:
USD 52.32M
Total debt:
USD 1.84M
EPS:
USD -0.99

What stands out

  • Free cash flow is USD -29.63M, negative for the stored period.
  • The balance sheet shows USD 52.32M of cash versus USD 1.84M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 50.49M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for EPRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can EPRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is EPRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for EPRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of EPRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research EPRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.